BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17710657)

  • 1. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
    Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
    Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
    Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
    Janeway KA; Grier HE
    Lancet Oncol; 2010 Jul; 11(7):670-8. PubMed ID: 20347613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study.
    Nooij MA; Whelan J; Bramwell VH; Taminiau AT; Cannon S; Hogendoorn PC; Pringle J; Uscinska BM; Weeden S; Kirkpatrick A; Glabbeke Mv; Craft AW;
    Eur J Cancer; 2005 Jan; 41(2):225-30. PubMed ID: 15661546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of amifostine in the therapy of osteosarcoma in children and adolescents.
    Petrilli AS; Oliveira DT; Ginani VC; Kechichian R; Dishtchekenian A; Filho Wde M; Tanaka C; Dias CG; Latorre Mdo R; Brunetto AL; Cardoso H; Almeida MT; de Camargo B
    J Pediatr Hematol Oncol; 2002; 24(3):188-91. PubMed ID: 11990304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy in osteosarcoma: the experience at the Hospital Infantil de Mexico from August 1996 to August 1999.
    Gallegos-Castorena S; Martínez-Avalos A; Medina-Sansón A; Juárez-Villegas L; Guerrero-Avendaño G; Sadowinski-Pine S
    Med Pediatr Oncol; 2001 Mar; 36(3):407. PubMed ID: 11241450
    [No Abstract]   [Full Text] [Related]  

  • 12. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
    Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
    Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
    Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
    Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic osteosarcoma.
    Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
    Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intra-arterial chemotherapy and embolization before limb salvage surgery for osteosarcoma of the lower extremity.
    Zhang HJ; Yang JJ; Lu JP; Lai CJ; Sheng J; Li YX; Hao Q; Zhang SM; Gupta S
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):672-8. PubMed ID: 19296158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma.
    Longhi A; Pignotti E; Versari M; Asta S; Bacci G
    Oncol Rep; 2003; 10(1):151-5. PubMed ID: 12469162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma.
    Longhi A; Ferrari S; Bacci G; Specchia S
    Anticancer Drugs; 2007 Jul; 18(6):737-44. PubMed ID: 17762406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.